Novo Nordisk CEO To Focus On U.S. As COO Schultz Gains Extra Duties
This article was originally published in The Pink Sheet Daily
Executive Summary
The sharing of executive responsibilities with Kare Schultz frees up CEO Lars Sorensen to focus on key growth markets, as Novo Nordisk faces growing competitive pressures from generics, new diabetes market entrants and a tougher pricing environment.